A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Conditions: Meningococcal Meningitis Interventions: Biological: batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4); Biological: batch 2 of MCV4; Biological: batch 3 of MCV4; Biological: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Sponsors: CanSino Biologics Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials